专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07501496B1 Anti-OX40L antibodies 有权
标题翻译：抗OX40L抗体
公开(公告)号：US07501496B1
公开(公告)日：2009-03-10
申请号：US11229162
申请日：2005-09-16
申请人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
发明人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
IPC分类号： C07K16/00 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2875 , C07K2317/21 , C07K2317/52 , C07K2317/56
摘要： This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
摘要翻译：本发明涉及抗OX40L抗体，特别涉及抗OX40L抗体及其变体，其含有源自人源的Fc部分，并且不结合补体因子C1q。这些抗体具有新的和本发明的性质，为患有炎性疾病的患者带来益处。

12. 发明申请

US20110070239A1 ANTI-OX40L ANTIBODIES 审中-公开
标题翻译：抗OX40L抗体
公开(公告)号：US20110070239A1
公开(公告)日：2011-03-24
申请号：US12958278
申请日：2010-12-01
申请人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
发明人： Joseph Endl , Elsie M. Eugui , Maria Elena Fuentes , Yvo Graus , Aran Frank Labrijn , Martin Lanzendoerfer , Paul Parren , Frank Rebers , Ralf Schumacher , Stefan Seeber , Jan Van De Winkel , Martine Van Vugt
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/074
CPC分类号： C07K16/2875 , C07K2317/21 , C07K2317/52 , C07K2317/56
摘要： This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
摘要翻译：本发明涉及抗OX40L抗体，特别涉及抗OX40L抗体及其变体，其含有源自人源的Fc部分，并且不结合补体因子C1q。这些抗体具有新的和本发明的性质，为患有炎性疾病的患者带来益处。

13. 发明授权

US07807158B2 Antibodies against IL-13 receptor alpha1 and uses thereof 有权
标题翻译：针对IL-13受体α1的抗体及其用途
公开(公告)号：US07807158B2
公开(公告)日：2010-10-05
申请号：US11325197
申请日：2006-01-03
申请人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： The instant specification discloses an antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.
摘要翻译：本说明书公开了结合IL-13Rα1的抗体，抑制IL-13生物活性并包含可变重链和可变轻链，其特征在于该抗体的可变重链氨基酸序列CDR3选自 SEQ ID NO：1,3,5,7或9的重链CDR3序列，该抗体可用于治疗哮喘和过敏性疾病。

14. 发明申请

US20130209355A1 ANTIBODIES AGAINST HUMAN CD38 有权
标题翻译：抗人CD38抗体
公开(公告)号：US20130209355A1
公开(公告)日：2013-08-15
申请号：US13702857
申请日：2011-06-08
申请人： Michel De Weers , Tim Walseth , Jan Van De Winkel , Tom Vink , Paul Parren
发明人： Michel De Weers , Tim Walseth , Jan Van De Winkel , Tom Vink , Paul Parren
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , C07K16/2896 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/76 , G01N33/573 , G01N2333/91148
摘要： Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
摘要翻译：公开了结合人CD38和相关的基于抗体的组合物和分子的分离的单克隆抗体。还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

15. 发明授权

US09068011B2 Monoclonal antibodies against c-Met 有权
标题翻译：针对c-Met的单克隆抗体
公开(公告)号：US09068011B2
公开(公告)日：2015-06-30
申请号：US13583743
申请日：2011-03-10
申请人： Joost J. Neijssen , Bart De Goeij , Edward Norbert Van Den Brink , Aran Frank Labrijn , Rene Hoet , Janine Schuurman , Paul Parren , Jan Van De Winkel
发明人： Joost J. Neijssen , Bart De Goeij , Edward Norbert Van Den Brink , Aran Frank Labrijn , Rene Hoet , Janine Schuurman , Paul Parren , Jan Van De Winkel
IPC分类号： C07K16/30 , C07K16/40 , C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC分类号： C07K16/3076 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/71 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N33/5748 , G01N2333/912
摘要： Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
摘要翻译：公开了结合人c-Met，肝细胞生长因子受体以及相关的基于抗体的组合物和分子的分离的单克隆抗体。还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

16. 发明申请

US20100267934A1 STABLE IGG4 ANTIBODIES 审中-公开
标题翻译：稳定的IGG4抗体
公开(公告)号：US20100267934A1
公开(公告)日：2010-10-21
申请号：US12602439
申请日：2008-05-30
申请人： Jan Van De Winkel , Tom Vink , Janine Schuurman , Paul Parren , Rob Aalberse , Marijn Van Der Neut Kolfschote
发明人： Jan Van De Winkel , Tom Vink , Janine Schuurman , Paul Parren , Rob Aalberse , Marijn Van Der Neut Kolfschote
IPC分类号： C07K16/24 , C07K16/18 , C12P21/08
CPC分类号： C07K16/2887 , A61K47/6803 , A61K47/6813 , A61K47/6835 , A61K47/6839 , A61K47/6845 , A61K47/6849 , A61K51/10 , A61K51/1006 , A61K51/1021 , A61K51/1027 , A61K51/103 , A61K51/1039 , A61K2039/505 , C07K16/00 , C07K16/16 , C07K16/18 , C07K16/28 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/94
摘要： The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
摘要翻译：本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区，位置（405）或位置（370）处的Lys残基。

17. 发明申请

US20090117584A1 Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins 审中-公开
标题翻译：非人类哺乳动物关节炎模型，具有针对柑橘色素蛋白的人类抗体
公开(公告)号：US20090117584A1
公开(公告)日：2009-05-07
申请号：US11922990
申请日：2006-06-29
申请人： Rene Toes , Thomas Huizinga , Miranda Molenaar , Paul Parren , Jan Van De Winkel
发明人： Rene Toes , Thomas Huizinga , Miranda Molenaar , Paul Parren , Jan Van De Winkel
IPC分类号： G01N33/53 , A01K67/00
CPC分类号： G01N33/5088
摘要： Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).
摘要翻译：使用非人哺乳动物疾病模型，其中所述非人哺乳动物已经植入人滑膜组织或其它含有抗CCP（环状瓜氨酸化肽）抗体产生细胞的人发炎组织，用于（i）分析疾病中的细胞过程与所述人滑膜组织或其他人发炎组织中的抗CCP抗体相关，（ii）研究抗CCP抗体在与抗CCP抗体相关的疾病的诱导和进展中的作用，（iii）测试抗CCP抗体用于预防或治疗与抗CCP抗体相关的疾病的治疗剂，和（iv）鉴定可用于预防或治疗与抗CCP抗体相关的疾病的治疗剂。在一个实施方案中，非人哺乳动物疾病模型是小鼠，例如SCID小鼠，并且与抗CCP抗体相关的疾病是关节炎，例如RA（类风湿性关节炎）。

18. 发明申请

US20130216548A1 MONOCLONAL ANTIBODIES AGAINST C-MET 有权
公开(公告)号：US20130216548A1
公开(公告)日：2013-08-22
申请号：US13583743
申请日：2011-03-10
申请人： Joost J. Neijssen , Bart De Goeij , Edward Norbert Van Den Brink , Aran Frank Labrijn , Rene Hoet , Janine Schuurman , Paul Parren , Jan Van De Winkel
发明人： Joost J. Neijssen , Bart De Goeij , Edward Norbert Van Den Brink , Aran Frank Labrijn , Rene Hoet , Janine Schuurman , Paul Parren , Jan Van De Winkel
IPC分类号： C07K16/40 , A61K45/06 , A61K39/395
CPC分类号： C07K16/3076 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/71 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N33/5748 , G01N2333/912
摘要： Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

19. 发明申请

US20130171148A1 MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE 有权
标题翻译：抗黑素抗体的单克隆抗体
公开(公告)号：US20130171148A1
公开(公告)日：2013-07-04
申请号：US13700246
申请日：2011-05-27
申请人： Bart De Goeij , Edward Norbert Van Den Brink , Simone De Haij , Thilo Riedl , Rene Hoet , Ole Baadsgaard , David Satijn , Jan Van De Winkel , Paul Parren
发明人： Bart De Goeij , Edward Norbert Van Den Brink , Simone De Haij , Thilo Riedl , Rene Hoet , Ole Baadsgaard , David Satijn , Jan Van De Winkel , Paul Parren
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/32 , C07K2317/21 , C07K2317/33 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , Y02A50/472
摘要： Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
摘要翻译：公开了与人表皮生长因子受体2（HER2）结合的分离的单克隆抗体以及相关的基于抗体的组合物和分子。还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

20. 发明申请

US20110086366A1 METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES 审中-公开
标题翻译： IGG4抗体治疗不良事件的风险评估方法
公开(公告)号：US20110086366A1
公开(公告)日：2011-04-14
申请号：US12918768
申请日：2009-02-20
申请人： Aran Frank Labrijn , Janine Schuurman , Jan Van De Winkel , Paul Parren
发明人： Aran Frank Labrijn , Janine Schuurman , Jan Van De Winkel , Paul Parren
IPC分类号： G01N33/53
CPC分类号： G01N33/6854 , G01N2800/50 , Y02A50/53
摘要： The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies.
摘要翻译：本发明涉及用于评估个体在用能够进行Fab-臂交换的治疗性抗体治疗后发展不良事件的风险的方法和试剂盒，所述方法包括以下步骤：a）从作为用所述治疗性抗体治疗的候选者的个体，b）测定所述样品是否存在结合已知或怀疑与所述不良事件的致病因子相关联的抗原的循环IgG4抗体，以及c）步骤b）的测定结果的基础，个体在用治疗性抗体治疗后将发展出所述不良事件的风险，其中所述不良事件发展的风险随着所述循环IgG4抗体水平的增加而增加。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式